Hereditary Corpoporphyria Presenting with Deep Jaundice and Photosensitivity

Total Page:16

File Type:pdf, Size:1020Kb

Hereditary Corpoporphyria Presenting with Deep Jaundice and Photosensitivity ANNALS OF GASTROENTEROLOGY 2001, 14(4):319-324 Case report Hereditary corpoporphyria presenting with deep jaundice and photosensitivity D. Kapetanos, P. Xiarhos, E. Kapetis1, A. Avgerinos, A. Ilias, G. Kokozidis, G. Kitis CASE REPORT SUMMARY A 20-year old woman was referred to our department Hereditary coproporphyria is a rare hepatic porphyria with from another hospital in May 2000, due to painless jaun- symptoms similar to acute intermittent porphyria. Photo- dice and pruritus. She reported having dark urine and sensitivity is not described in the latter. We report the case pale stools for two weeks and jaundice for 10 days be- of a young female with deep jaundice, photosensitivity, ane- fore admission. mia, renal failure and no abdominal pain. Hereditary co- proporphyria was diagnosed and the patient was discharged The patient had no past medical history, with no ne- after 111 days in full recovery. She was readmitted after 45 onatal jaundice, had received no medications during the days with abdominal pain and no jaundice or photosensi- previous months and had no alcohol consumption in the tivity. Severe neuropathy developed which caused tetrapare- past. She was on a diet in order to lose weight (her initial sis and deterioration of the respiratory muscle function. weight was 80 kg) and had been using home insecticides Haem arginate was administered with gradual improvement several days before. Her parents reported a family histo- of neuropathy. ry of thalassemia major. Key words: Hereditary corpoporphyria, jaundice, photosen- On admission she was icteric. She had 2-3 blisters on sitivity, neuropathy, haem arginate her face with serous yellow colored fluid. The blood pres- sure was 100/70 mm Hg, the pulse was 60 per minute INTRODUCTION and the temperature was normal. The liver was not pal- pable but the spleen was palpable 2 cm below the costal Hereditary coproporphyria is a very rare hepatic por- margin. There was no lymphadenopathy and no signs of phyria with clinical presentation similar to acute inter- ascites or peripheral edema. Heart sounds and pulmo- mittent porphyria, except that cutaneous photosensitivi- nary auscultation were normal. ty is also present in 30% of cases of the former. We The results of the hematological and biochemical present a young female with acute cholestasis and cuta- analysis on different days of her hospitalization are shown neous photosensitivity without neurological symptoms at in Table 1. HBsAg, anti-HBs, HBeAg, anti-HBe, anti- presentation, who proved to have hereditary copropor- Hbc, anti-HCV, HCV-RNA by PCR, IgM anti-HAV, phyria. anti-HIV1,2, IgM anti-CMV, IgM anti-EBV, IgM anti- HSV1,2 were negative. Antinuclear, antimitochondrial and anti-smooth muscle antibodies were also negative. Gastroenterology Department, George Papanikolaou Hospital, Serum ceruloplasmine was 0,49gr/L (normal 0,22-0,58) Thessaloniki, Greece, 1Histopathology Laboratory, Department of and copper 1,68ìg/ml (normal 0,7-1,4) and 24hour urine Dermatology, Aristotles University of Thessaloniki copper was 300ìg/ml (normal<100). Serum immu- noglobulins were: IgA 126mg/dl, IgG 395mg/dl, IgM Author for correspondence: 69mg/dl. a-1 antithrypsin was 211ìg/dl (93-224). No Keis- George Kitis, 19, Anixeos str., 552 36 Thessaloniki, Greece, Tel.: er-Fleischer rings were detected. Tuberculin test and +31-350102, Fax: +31-350050, e-mail: [email protected] multiple blood cultures were negative. 320 D. KAPETANOS et al Table 1. Hematological and biochemical values Day 1 Day 24 Day 45 Day 66 Day 111 Day 139 Leucocytes k/ìl 7 11,6 10,6 16,7 5 6 Hb g/dl 9,4 6,9 11,8 8,1 8,2 9,8 PLS k/ìl 116 233 91 155 112 120 PT sec 12/12 12,5/10,5 13/10.5 12,8/10,5 10,6/10,5 11/11 LDH IU/L 247 312 401 349 130 143 AST IU/L 57 66 48 85 41 25 ALT IU/L 56 60 80 88 29 17 ã-GT IU/L 13 16 47 29 29 22 ALP IU/L 256 224 190 288 145 148 Protein g/dl 5,8 5,6 6,1 5 6,2 6,9 Albumin g/dl 3,1 3,3 4,3 3,2 4,4 4,6 Bilirubin mg/dl 14,6 47 63,9 45,4 5,8 1,9 Direct bil. 10,35 44 45,8 33,8 4,4 0,58 Glucose mg/dl 92 139 90 85 75 91 Urea mg/dl 17 143 89 76 48 36 K meq/L 4,9 3,4 4 4,1 4,5 4,7 Na meq/L 149 138 136 134 146 145 Creatinin mg/dl 0,9 4,3 1 2,7 0,9 1,1 Blood hemoglobin was 9,4g/dl on admission, but it and compartmentalization of the liver parenchyma. Be- gradually fell to 6,9g/dl. MCV was 63,7, MCH 20,2, cause of these findings she underwent an ERCP, which MCHC 31,6. Reticulocyte count was 2,1%. Serum iron is a much more sensitive diagnostic method than MRCP, was 73ìg/dl and ferritin 18,1ng/ml. Gene analysis by PCR for detecting bile duct abnormalities, that revealed nor- for C282Y and H63D mutations of the hemochromato- mal bile duct appearance. Mild duodenitis was found on sis HFE gene was negative. Direct and indirect Coombs esophago-gastro-duodenoscopy. test were negative. The examination of the G6PD en- The percutaneous liver biopsy showed normal hepatic zyme was normal. Red cell osmotic resistance was in- architecture. There was diffuse cholestasis, mainly ex- creased and the sickle test was negative. Hemoglobin tracellular and marked portal inflammation with poly- electrophoresis was normal. She had no obvious blood morphonuclear cells. The inflammatory cells were de- loss. Twelve units of red cells were transfused during her stroying the wall of the bile ducts and epithelium and hospitalization. A bone marrow aspiration showed in- entered the lumen. There was mild intralobular inflam- creased cellularity, indicating that anemia and thrombo- mation and no fibrosis. cytopenia was caused by peripheral destruction. This was attributed to hypersplenism. Following her admission the jaundice worsened and the blisters extended to the extremities but not the body. Abdominal ultrasound revealed homogenous echo- The fluid in the blisters was yellow at the beginning and genicity of the liver with normal intrahepatic and extra- it subsequently turned to hemorrhagic. The blisters were hepatic ducts. The gallbladder was normal. There was broken to eschars and healed, leaving discoloration of portal and splenic vein dilatation (18mm and 12mm re- the epidermis, while new lesions appeared elsewhere spectively). The spleen diameter was 126mm. (Figure 1, 2, 3). A skin biopsy showed subdermal blisters Computerized tomography of the abdomen and tho- with red cells but no inflammatory cells. The findings rax was performed (without contrast medium, due to in- were compatible to porphyria. tercurrent renal failure). It revealed ground glass appear- A urine porphyrin test was 13943ìg/24h (nor- ance in the right lung with no other abnormal findings. mal<150). Blood, urine and feces samples were sent to MRI of the upper abdomen and MRCP were performed Kings College Hospital (SAS Porphyria Service), Lon- and showed normal bile ducts, with surrounding fibrosis don. The results are shown in Table 2. It was concluded Hereditary corpoporphyria presenting with deep jaundice and photosensitivity 321 that the patient had hereditary coproporphyria. Ten days after her admission she started to develop renal failure with normal urine output. There were no casts or red cells on urine examination. Excretion of so- dium was 39mmol/24h. She underwent plasma exchange and hemodialysis that improved renal function tests but had no effect on jaundice. Fifty days after her admission she developed an un- explained nonproductive cough disturbing her, especially in the supine position, that was not relieved by the usual symptomatic measures. Spirometry was normal. She also developed dystrophic nail changes and alopecia, although she had good nutrition. A liver biopsy performed two months after the first biopsy, showed bile duct proliferation, biliary and fibro- sing piecemeal necrosis and multiple areas with hepato- cellular necrosis. Fibrosis in this biopsy was probably the result of a healing process. The patient showed gradual improvement and was discharged 111 days after her admission, with no jaun- dice or photosensitivity (Figure 4, 5). Forty-five days later she was readmitted to our de- partment with abdominal pain, which, after thorough examination, was attributed to an acute attack of por- phyria. She had no fever, jaundice or photosensitivity. She was given 400gr glucose i.v. daily for a few days with- out improvement. On the contrary, she developed neu- ropathy, which caused tetraparesis and deterioration of the respiratory muscle function although blood gases remained normal. Haem arginate (Normosang) was ad- ministered (3mg/Kg daily for ten days) with gradual im- provement and she was discharged two months after her admission. On February 2001 the patient was last seen in the outpatient clinic and she was able to move her hands and walk with assistance. She had no jaundice or photosensi- tivity. DISCUSSION Hereditary coproporphyria (HCP) is a very rare dis- order. It is inherited in an autosomal dominant mode but fewer than 30% of patients have an acute attack. Its incidence has been estimated in Denmark to be 2 per million,1 in Czech Republic 1:1700002 and in Japan 1:184000.3 The disease usually presents with symptoms identical to those of acute intermittent porphyria (AIP). Figures 1, 2, 3. Skin changes a few days after admission. Photosensitivity resembling that of porphyria cutanea 322 D. KAPETANOS et al Table 2. Porphyrin analysis of urine, blood and faeces samples Random urine 5-aminolaevulinic acid (ALA) 4,8 ìmol/mmol creat (normal <3,8) Porphobilinogen (PBG) 1 ìmol/mmol creat (normal <1,5) Total porphyrin 2770 ìmol/mmol creat (normal <35) Uroporphyrin I 97 nmol/L Uroporphyrin III 52 nmol/L Total uroporphyrin (I+III) 149 nmol/L (normal <24) Heptacarboxylate porphyrin 57 nmol/L (normal <4) Coproporphyrin I 2010 nmol/L Coproporphyrin III 11800 nmol/L Total coproporphyrin (I+III) 13810 nmol/L (normal<115) Urine creatinine 5,6 mmol/L Blood Excitation maximum 401 nm Emission maximum 618 nm Faeces Coproporphyrin I 180 nmol/g dry wt Coproporphyrin III 2750 nmol/g dry wt Total coproporphyrin (I+III) 2930 nmol/g dry wt (normal <46) Dicarboxylate porphyrin (protoporphyrin) 230 nmol/g dry wt (normal <134) tarda (PCT) is seen in about 30 per cent, a finding that viral hepatitis or renal failure.
Recommended publications
  • Liver Transplantation for the Management of Acute Intermittent
    nd Gas y a tro g in lo t o e t s a t i p n Journal of Hepatology and e a l H D f i o s Kappus at al., J Hepatol Gastroint Dis 2017, 3:1 l o a r d ISSN:n 2475-3181 r e u r s o J Gastrointestinal Disorders DOI: 10.4172/2475-3181.1000141 Case Report Open Access Liver Transplantation for the Management of Acute Intermittent Porphyria: A Case Report Matthew R Kappus1, Bryant B Summers2, Jennifer S Byrns2*, Carl L Berg1 and Julius M Wilder1 1Division of Gastroenterology, Duke University School of Medicine, Durham NC, United States 2Department of Pharmacy, Duke University Hospital, Durham NC, United States *Corresponding author: Jennifer S Byrns, Department of Pharmacy, Duke University Hospital, DUMC BOX 3089, Durham, NC 27710, United States, Tel: 919-681-0677; E-mail: [email protected] Received date: December 27, 2016; Accepted date: January 16, 2017; Published date: January 20, 2017 Copyright: © 2017 Kappus MR, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract We report a single patient with acute intermittent porphyria whose porphyria was successfully treated with orthotopic liver transplantation. She had a very poor quality of life as a result of years of frequent acute porphyria symptoms manifesting as abdominal pain crises. After transplantation, clinical signs of porphyria resolved as expected. This case adds to a growing body of literature which is assisting to formulate the indications for, and the timing of, transplantation for AIP.
    [Show full text]
  • Module 01: Classification of Porphyria
    MODULE 01 Classification of Porphyria Do not reprint, reproduce, modify or distribute this material without the prior written permission of Alnylam Pharmaceuticals. © 20120199 Alnylam PharmaceuticalsPharmaceuticals,, Inc.Inc. All rights reserved. -USA-00001-092018 1 Porphyria—A Rare Disease of Clinical Consequence • Porphyria is a group of at least 8 metabolic disorders1,2 – Each subtype of porphyria involves a genetic defect in a heme biosynthesis pathway enzyme1,2 – The subtypes of porphyria are associated with distinct signs and symptoms in patient populations that can differ by gender and age1,3 • Prevalence of some subtypes of porphyria may be higher than generally assumed3 Estimated Prevalence of Most Common Subtypes of Porphyria1,4 Estimated Prevalence Based on European Subtype of Porphyria and US Data Porphyria cutanea tarda (PCT) 1/10,000 (EU)1 0.118-1/20,000 (EU)1,4 Acute intermittent porphyria (AIP) 5/100,000 (US)1 Erythropoietic protoporphyria (EPP) 1/50,000-75,000 (EU)1 1. Ramanujam V-MS, Anderson KE. Curr Protoc Hum Genet. 2015;86:17.20.1-17.20.26. 2. Puy H et al. Lancet. 2010;375:924-937. 3. Bissell DM et al. N Engl J Med. 2017;377:862-872. 4. Elder G et al. J Inherit Metab Dis. 2013;36:848-857. Do not reprint, reproduce, modify or distribute this material without the prior written permission of Alnylam Pharmaceuticals. © 2019 Alnylam Pharmaceuticals, Inc. All rights reserved. -USA-00001-092018 2 Classification of Porphyria Porphyria can be classified in 2 major ways1,2: 1 According to major physiological sites: liver or 2 According to major clinical manifestations1,2 bone marrow1,2 • Heme precursors originate in either the liver or Acute Versus Photocutaneous Porphyria bone marrow, which are the tissues most • Major clinical manifestations are either neurovisceral active in heme biosynthesis1,2 symptoms (eg, severe, diffuse abdominal pain) associated with acute exacerbations or cutaneous lesions resulting from phototoxicity1,2 • Acute hepatic porphyria may be somewhat of a misnomer since the clinical features may be prolonged and chronic3 1.
    [Show full text]
  • Advances in Hematology
    ADVANCES IN HEMATOLOGY Current Developments in the Management of Hematologic Disorders Hematology Section Editor: Craig M. Kessler, MD What Hematologists Need to Know About Acute Hepatic Porphyria Manisha Balwani, MD, MS Associate Professor Department of Genetics and Genomic Sciences Icahn School of Medicine at Mount Sinai New York, New York H&O What is porphyria? H&O How common is acute hepatic porphyria? MB The porphyrias encompass a group of inherited MB Based on estimates from Western Europe, the metabolic disorders that result from a deficiency of one of combined prevalence of the acute hepatic porphyrias the enzymes in the heme biosynthetic pathway. These are among the white population is approximately 1 in genetic disorders; they can be inherited in an autosomal 200,000. These disorders are more common in certain dominant or recessive X-linked pattern; or they may be parts of the world because of founder mutations. For sporadic, as with porphyria cutanea tarda. example, the carrier frequency of acute intermittent porphyria is much higher in the Scandinavian countries, H&O How many types of porphyria exist? and variegate porphyria is much more common in South Africa.1 MB There are 8 different kinds of porphyria. These may be Even where the incidence is high, symptoms related classified as hepatic or erythropoietic based on the primary to these disorders remain rare. In fact, most patients who site of accumulation of porphyrins, but more commonly inherit a genetic change do not manifest symptoms of the they are classified clinically as acute or cutaneous. The acute disorder—the disease remains latent in a vast majority of hepatic porphyrias include acute intermittent porphyria these patients.
    [Show full text]
  • A High Urinary Urobilinogen / Serum Total Bilirubin Ratio Reported in Abdominal Pain Patients Can Indicate Acute Hepatic Porphyria
    A High Urinary Urobilinogen / Serum Total Bilirubin Ratio Reported in Abdominal Pain Patients Can Indicate Acute Hepatic Porphyria Chengyuan Song Shandong University Qilu Hospital Shaowei Sang Shandong University Qilu Hospital Yuan Liu ( [email protected] ) Shandong University Qilu Hospital https://orcid.org/0000-0003-4991-552X Research Keywords: acute hepatic porphyria, urinary urobilinogen, serum total bilirubin Posted Date: June 14th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-587707/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/10 Abstract Background: Due to its variable symptoms and nonspecic laboratory test results during routine examinations, acute hepatic porphyria (AHP) has always been a diagnostic dilemma for physicians. Misdiagnoses, missed diagnoses, and inappropriate treatments are very common. Correct diagnosis mainly depends on the detection of a high urinary porphobilinogen (PBG) level, which is not a routine test performed in the clinic and highly relies on the physician’s awareness of AHP. Therefore, identifying a more convenient indicator for use during routine examinations is required to improve the diagnosis of AHP. Results: In the present study, we retrospectively analyzed laboratory examinations in 12 AHP patients and 100 patients with abdominal pain of other causes as the control groups between 2015 and 2021. Compared with the control groups, AHP patients showed a signicantly higher urinary urobilinogen level during the urinalysis (P < 0.05). However, we showed that the higher urobilinogen level was caused by a false- positive result due to a higher level of urine PBG in the AHP patients. Hence, we used serum total bilirubin, an upstream substance of urinary urobilinogen synthesis, for calibration.
    [Show full text]
  • Acute Intermittent Porphyria: an Overview of Therapy Developments and Future Perspectives Focusing on Stabilisation of HMBS and Proteostasis Regulators
    International Journal of Molecular Sciences Review Acute Intermittent Porphyria: An Overview of Therapy Developments and Future Perspectives Focusing on Stabilisation of HMBS and Proteostasis Regulators Helene J. Bustad 1 , Juha P. Kallio 1 , Marta Vorland 2, Valeria Fiorentino 3 , Sverre Sandberg 2,4, Caroline Schmitt 3,5, Aasne K. Aarsand 2,4,* and Aurora Martinez 1,* 1 Department of Biomedicine, University of Bergen, 5020 Bergen, Norway; [email protected] (H.J.B.); [email protected] (J.P.K.) 2 Norwegian Porphyria Centre (NAPOS), Department for Medical Biochemistry and Pharmacology, Haukeland University Hospital, 5021 Bergen, Norway; [email protected] (M.V.); [email protected] (S.S.) 3 INSERM U1149, Center for Research on Inflammation (CRI), Université de Paris, 75018 Paris, France; valeria.fi[email protected] (V.F.); [email protected] (C.S.) 4 Norwegian Organization for Quality Improvement of Laboratory Examinations (Noklus), Haraldsplass Deaconess Hospital, 5009 Bergen, Norway 5 Assistance Publique Hôpitaux de Paris (AP-HP), Centre Français des Porphyries, Hôpital Louis Mourier, 92700 Colombes, France * Correspondence: [email protected] (A.K.A.); [email protected] (A.M.) Abstract: Acute intermittent porphyria (AIP) is an autosomal dominant inherited disease with low clinical penetrance, caused by mutations in the hydroxymethylbilane synthase (HMBS) gene, which encodes the third enzyme in the haem biosynthesis pathway. In susceptible HMBS mutation carriers, triggering factors such as hormonal changes and commonly used drugs induce an overproduction Citation: Bustad, H.J.; Kallio, J.P.; and accumulation of toxic haem precursors in the liver. Clinically, this presents as acute attacks Vorland, M.; Fiorentino, V.; Sandberg, characterised by severe abdominal pain and a wide array of neurological and psychiatric symptoms, S.; Schmitt, C.; Aarsand, A.K.; and, in the long-term setting, the development of primary liver cancer, hypertension and kidney Martinez, A.
    [Show full text]
  • Detecting Rare Diseases in Electronic Health Records Using Machine Learning and Knowledge Engineering: Case Study of Acute Hepatic Porphyria
    medRxiv preprint doi: https://doi.org/10.1101/2020.04.09.20052449; this version posted April 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Detecting Rare Diseases in Electronic Health Records Using Machine Learning and Knowledge Engineering: Case Study of Acute Hepatic Porphyria Aaron Cohen, MD, MS 1, Steven Chamberlin, ND 1, Thomas Deloughery, MD 1, Michelle Nguyen, BS 1, Steven Bedrick, PhD 1, Stephen Meninger, PharmD 2, John J. Ko, PharmD, MS 2, Jigar Amin, PharmD 2, Alex Wei, PharmD 2, William Hersh, MD 1 1Department of Medical Informatics & Clinical Epidemiology, School of Medicine, Oregon Health & Science University, Portland, OR USA. 2Alnylam Pharmaceuticals, Cambridge, MA, USA. Abstract Background With the growing adoption of the electronic health record (EHR) worldwide over the last decade, new opportunities exist for leveraging EHR data for detection of rare diseases. Rare diseases are often not diagnosed or delayed in diagnosis by clinicians who encounter them infrequently. One such rare disease that may be amenable to EHR-based detection is acute hepatic porphyria (AHP). AHP consists of a family of rare, metabolic diseases characterized by potentially life-threatening acute attacks and, for some patients, chronic debilitating symptoms that negatively impact daily functioning and quality of life. The goal of this study was to apply machine learning and knowledge engineering to a large extract of EHR data to determine whether they could be effective in identifying patients not previously tested for AHP who should receive a proper diagnostic workup for AHP.
    [Show full text]
  • The Little Imitator-Porphyria: a Neuropsychiatric Disorder
    Journal ofNeurology, Neurosurgery, and Psychiatry 1997;62:319-328 319 REVIEW J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.62.4.319 on 1 April 1997. Downloaded from The little imitator-porphyria: a neuropsychiatric disorder Helen L Crimlisk Abstract Porphyria is derived from the Greek word por- Three common subtypes of porphyria phuros meaning purple. Protoporphyrin IX is give rise to neuropsychiatric disorders; the biologically active substance, an important acute intermittent porphyria, variegate feature of which is its metal binding capacity. porphyria, and coproporphyria. The sec- Both chlorophyll and haem are metallopor- ond two also give rise to cutaneous symp- phyrins and are involved in the processes of toms. Neurological or psychiatric energy capture and utilisation in animals and symptoms occur in most acute attacks, plants. The description of the porphyrins by and may mimc many other disorders. Nobel laureate Hans Fischer' in 1930 as: The diagnosis may be missed because it is "The compounds which make grass green not even considered or because of techni- and blood red." cal problems, such as sample collection indicates the central position of these sub- and storage, and interpretation of results. stances in the biological sciences. A negative screening test does not exclude The porphyrias are a heterogeneous group the diagnosis. Porphyria may be overrep- of overproduction diseases, resulting from resented in psychiatric populations, but genetically determined, partial deficiencies in the lack of control groups makes this haem biosynthetic enzymes. Their manifesta- Department of uncertain. The management of patients tions are broad and their relevance in neu- Neuropsychiatry, with porphyria and psychiatric symptoms ropsychiatric disorders may sometimes be Institute ofNeurology, causes considerable Queen Square, problems.
    [Show full text]
  • Molecular Genetics of Variegate Porphyria in Finland
    Department of Medicine, Division of Endocrinology University of Helsinki, Finland MOLECULAR GENETICS OF VARIEGATE PORPHYRIA IN FINLAND Mikael von und zu Fraunberg Academic dissertation To be presented with the permission of the Medical Faculty of the University of Helsinki, for public examination in Auditorium II, Haartmaninkatu 8, Biomedicum Helsinki, on March 22th 2003, at 12:00 noon Helsinki 2003 SUPERVISED BY Docent Raili Kauppinen, M.D., Ph.D. Department of Medicine Division of Endocrinology University of Helsinki Finland REVIEWED BY Professor Richard J. Hift, M.D., Ph.D. Department of Medicine Lennox Eales Porphyria Laboratory MRC/UCT Liver Research Centre University of Cape Town South Africa and Professor Eeva-Riitta Savolainen, M.D., Ph.D. Department of Clinical Chemistry University of Oulu Finland OFFICIAL OPPONENT: Docent Katriina Aalto-Setälä, M.D., Ph.D. Department of Medicine University of Tampere Finland © Mikael von und zu Fraunberg ISBN 952-91-5643-X (paperback) ISBN 952-10-0970-5 (pdf) http://ethesis.helsinki.fi Helsinki 2003 Yliopistopaino to my family CONTENTS SUMMARY............................................................................................................... 6 ORIGINAL PUBLICATIONS................................................................................... 8 ABBREVIATIONS.................................................................................................... 9 INTRODUCTION ................................................................................................... 10 REVIEW
    [Show full text]
  • Acute Hepatic Porphyria Neuro-Visceral Crisis
    :: Acute hepatic porphyria neuro-visceral crisis - This document is a translation of the French recommendations drafted by Prof. Jean-Charles Deybach and Dr. Hervé Puy, reviewed and published by Orphanet in 2007. - Some of the procedures mentioned, particularly drug treatments, may not be validated in the country where you practice. - See also the emergency guidelines for cutaneous porphyrias Synonyms: Acute intermittent porphyria, Hereditary coproporphyria, Porphyria variegata Definition: Porphyrias are monogenic and autosomal genetic conditions and each is linked to a deficiency of haem metabolising enzymes. Acute porphyria with abdominal pain and/or neuro-psychiatric symptoms can cause serious emergencies and include: - Acute intermittent porphyria (AIP), - Hereditary coproporphyria (HC), - Porphyria variegata (PV). Porphyria variegata and Hereditary coproporphyria can have mixed cutaneous and/or neuro-psychiatric symptoms. Further information: See the Orphanet abstract Menu Pre-hospital emergency care Recommendations for hospital recommendations emergency departments Synonyms Emergency situations Aetiology Drug interactions Special risks in an emergency Anaesthesia Frequently used long term treatments Additional therapeutic measures and hospitalisation Complications Organ donation Specific medical care prior to hospitalisation Documentary resources For further information Pre-hospital emergency care recommendations Call for a patient suffering from acute hepatic porphyria neuro-visceral crisis Synonyms ` Acute intermittent porphyria,
    [Show full text]
  • Molecular Characterisation of Acute Intermittent Porphyria in South Africa…………
    MOLECULAR CHARACTERISATION OF ACUTE INTERMITTENT PORPHYRIA IN SOUTH AFRICA BY PHILIP HENDRIK FORTGENS STUDENT NUMBER: FRTPHI001 SUBMITTED TO THE UNIVERSITY OF CAPE TOWN In partial fulfilment of the requirements for the degree MMed (Chemical Pathology) Faculty of Health Sciences UniversityUNIVERSITY of OF CAPECape TOWN Town Date of submission: 17 February 2014 Supervisor: Prof P Meissner Division of Medical Biochemistry University of Cape Town The copyright of this thesis vests in the author. No quotation from it or information derived from it is to be published without full acknowledgement of the source. The thesis is to be used for private study or non- commercial research purposes only. Published by the University of Cape Town (UCT) in terms of the non-exclusive license granted to UCT by the author. University of Cape Town Declaration I, Philip Hendrik Fortgens, hereby declare that the work on which this dissertation/thesis is based is my original work (except where acknowledgements indicate otherwise) and that neither the whole work nor any part of it, as been, is being, or is to be submitted for another degree in this or any other university. I empower the university to reproduce for the purpose of research either the whole or any portion of the contents in any manner whatsoever. Signature:……………………………………….. Date:…………………………………………….. 2 Table of Contents Declaration………………………………………………………………………………… 2 Acknowledgements……………………………………………………………………….. 7 List of Abbreviations……………………………………………………………………... 8 PART A………………………………………………………………………………………..
    [Show full text]
  • An Inherited Enzymatic Defect in Porphyria Cutanea Tarda: Decreased Uroporphyrinogen Decarboxylase Activity
    An inherited enzymatic defect in porphyria cutanea tarda: decreased uroporphyrinogen decarboxylase activity. J P Kushner, … , A J Barbuto, G R Lee J Clin Invest. 1976;58(5):1089-1097. https://doi.org/10.1172/JCI108560. Research Article Uroporphyrinogen decarboxylase activity was measured in liver and erythrocytes of normal subjects and in patients with porphyria cutanea tarda and their relatives. In patients with porphyria cutanea tarda, hepatic uroporphyrinogen decarboxylase activity was significantly reduced (mean 0.43 U/mg protein; range 0.25-0.99) as compared to normal subjects (mean 1.61 U/mg protein; range 1.27-2.42). Erythrocyte uroporphyrinogen decarboxylase was also decreased in patients with porphyria cutanea tarda. The mean erythrocyte enzymatic activity in male patients was 0.23 U/mg Hb (range 0.16-0.30) and in female patients was 0.17 U/mg Hb (range 0.15-0.18) as compared with mean values in normal subjects of 0.38 U/mg Hb (range 0.33-0.45) in men and 0.26 U/mg Hb (range 0.18-0.36) in women. With the erythrocyte assay, multiple examples of decreased uroporphyrinogen decarboxylase activity were detected in members of three families of patients with porphyria cutanea tarda. In two of these families subclinical porphyria was also recognized. The inheritance pattern was consistant with an autosomal dominant trait. The difference in erythrocyte enzymatic activity between men and women was not explained but could have been due to estrogens. This possibility was supported by the observation that men under therapy with estrogens for carcinoma of the prostate had values in the normal female range.
    [Show full text]
  • Highly Specialised Technology Evaluation Givosiran For
    Highly Specialised Technology Evaluation Givosiran for treating acute hepatic porphyria [ID1549] Evaluation Report © National Institute for Health and Care Excellence 2021. All rights reserved. See Notice of Rights. The content in this publication is owned by multiple parties and may not be re-used without the permission of the relevant copyright owner. NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Highly Specialised Technology Evaluation Givosiran for treating acute hepatic porphyria [ID1549] Contents: The following documents are made available to consultees and commentators: The final scope and final stakeholder list are available on the NICE website. 1. Company submission from Alnylam 2. Company clarification response 3. Consultee submissions from: a. British Porphyria Association: i. Submission ii. Supporting document on patient case studies b. Global Porphyria Advocacy Coalition submission c. National Acute Porphyria Service, Cardiff and Vale UHB d. National Acute Porphyria Service, King’s College Hospital NHS Foundation Trust e. NHS England and Improvement 4. Evidence Review Group report prepared by PenTAG 5. Evidence Review Group report – factual accuracy check 6. Evidence Review Group addendum Please note that the appendices to the company’s submission and company model will be available as a separate file on NICE Docs for information only. Any information supplied to NICE which has been marked as confidential has been redacted. All personal information has also been redacted. © National Institute for Health and Care Excellence
    [Show full text]